|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsochatzis EA, Meyer T and Burroughs AK:
Hepatocellular carcinoma. N Engl J Med. 366:92–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bertino G, Demma S, Ardiri A, Proiti M,
Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M,
Malaguarnera M and Di Carlo I: Hepatocellular carcinoma: Novel
molecular targets in carcinogenesis for future therapies. Biomed
Res Int. 2014:2036932014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mercado MA, Medina H, Rossano A, Acosta E,
Rodríguez M, Chan C and Orozco H: Metastatic disease of the liver:
Surgical perspective. Rev Gastroenterol Mex. 62:235–238. 1997.(In
Spanish). PubMed/NCBI
|
|
6
|
Wang F, Xie C, Zhao W, Deng Z, Yang H and
Fang Q: Long non-coding RNA CARLo-5 expression is associated with
disease progression and predicts outcome in hepatocellular
carcinoma patients. Clin Exp Med. 17:33–43. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maluccio M and Covey A: Recent progress in
understanding, diagnosing, and treating hepatocellular carcinoma.
CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xia L, Huang W, Tian D, Zhu H, Qi X, Chen
Z, Zhang Y, Hu H, Fan D, Nie Y and Wu K: Overexpression of forkhead
box C1 promotes tumor metastasis and indicates poor prognosis in
hepatocellular carcinoma. Hepatology. 57:610–624. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ørom UA, Derrien T, Beringer M, Gumireddy
K, Gardini A, Bussotti G, Lai F, Zytnicki M, Notredame C, Huang Q,
et al: Long noncoding RNAs with enhancer-like function in human
cells. Cell. 143:46–58. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen X, Bo L, Zhao X and Chen Q:
MicroRNA-133a inhibits cell proliferation, colony formation
ability, migration and invasion by targeting matrix
metallopeptidase 9 in hepatocellular carcinoma. Mol Med Rep.
11:3900–3907. 2015.PubMed/NCBI
|
|
11
|
Zhang W, Liu K, Liu S, Ji B, Wang Y and
Liu Y: MicroRNA-133a functions as a tumor suppressor by targeting
IGF-1R in hepatocellular carcinoma. Tumour Biol. 36:9779–9788.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Y, Wu C, Wang Y, Wen S, Wang J, Chen
Z, He Q and Feng D: MicroRNA-145 inhibits cell proliferation by
directly targeting ADAM17 in hepatocellular carcinoma. Oncol Rep.
32:1923–1930. 2014.PubMed/NCBI
|
|
13
|
Ruan T, He X, Yu J and Hang Z:
MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo
signaling and tumorigenesis in hepatocellular carcinoma. Oncol
Lett. 11:2941–2945. 2016.PubMed/NCBI
|
|
14
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pillai RS, Bhattacharyya SN, Artus CG,
Zoller T, Cougot N, Basyuk E, Bertrand E and Filipowicz W:
Inhibition of translational initiation by Let-7 MicroRNA in human
cells. Science. 309:1573–1576. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li X, Liu X, Fang J, Li H and Chen J:
microRNA-363 plays a tumor suppressive role in osteosarcoma by
directly targeting MAP2K4. Int J Clin Exp Med. 8:20157–20167.
2015.PubMed/NCBI
|
|
22
|
Song B, Yan J, Liu C, Zhou H and Zheng Y:
Tumor suppressor role of miR-363-3p in gastric cancer. Med Sci
Monit. 21:4074–4080. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsuji S, Kawasaki Y, Furukawa S, Taniue K,
Hayashi T, Okuno M, Hiyoshi M, Kitayama J and Akiyama T: The
miR-363-GATA6-Lgr5 pathway is critical for colorectal
tumourigenesis. Nat Commun. 5:31502014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qiao J, Lee S, Paul P, Theiss L, Tiao J,
Qiao L, Kong A and Chung DH: miR-335 and miR-363 regulation of
neuroblastoma tumorigenesis and metastasis. Surgery. 154:226–233.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun Q, Zhang J, Cao W, Wang X, Xu Q, Yan
M, Wu X and Chen W: Dysregulated miR-363 affects head and neck
cancer invasion and metastasis by targeting podoplanin. Int J
Biochem Cell Biol. 45:513–520. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang R, Li Y, Dong X, Peng L and Nie X:
MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1
in breast cancer. Med Oncol. 31:3472014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Y, Lu X, Wu B, Su Y, Li J and Wang H:
MicroRNA 363 mediated positive regulation of c-myc translation
affect prostate cancer development and progress. Neoplasma.
62:191–198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Georgieva B, Milev I, Minkov I, Dimitrova
I, Bradford AP and Baev V: Characterization of the uterine
leiomyoma microRNAome by deep sequencing. Genomics. 99:275–281.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu F, Min J, Cao X, Liu L, Ge Z, Hu J and
Li X: MiR-363-3p inhibits the epithelial-to-mesenchymal transition
and suppresses metastasis in colorectal cancer by targeting Sox4.
Biochem Biophys Res Commun. 474:35–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chapman BV, Wald AI, Akhtar P, Munko AC,
Xu J, Gibson SP, Grandis JR, Ferris RL and Khan SA: MicroRNA-363
targets myosin 1B to reduce cellular migration in head and neck
cancer. BMC Cancer. 15:8612015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ou Y, Zhai D, Wu N and Li X:
Downregulation of miR-363 increases drug resistance in
cisplatin-treated HepG2 by dysregulating Mcl-1. Gene. 572:116–122.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jackson RJ and Standart N: How do
microRNAs regulate gene expression? Sci STKE.
2007.re12007.PubMed/NCBI
|
|
33
|
Chang WC and Hung JJ: Functional role of
post-translational modifications of Sp1 in tumorigenesis. J Biomed
Sci. 19:942012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yue L, Li L, Liu F, Hu N, Zhang W, Bai X,
Li Y, Zhang Y, Fu L, Zhang X and Ye L: The oncoprotein HBXIP
activates transcriptional coregulatory protein LMO4 via Sp1 to
promote proliferation of breast cancer cells. Carcinogenesis.
34:927–935. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yin P, Zhao C, Li Z, Mei C, Yao W, Liu Y,
Li N, Qi J, Wang L, Shi Y, et al: Sp1 is involved in regulation of
cystathionine γ-lyase gene expression and biological function by
PI3K/Akt pathway in human hepatocellular carcinoma cell lines. Cell
Signal. 24:1229–1240. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pathi S, Jutooru I, Chadalapaka G, Nair V,
Lee SO and Safe S: Aspirin inhibits colon cancer cell and tumor
growth and downregulates specificity protein (Sp) transcription
factors. PLoS One. 7:e482082012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yuan P, Wang L, Wei D, Zhang J, Jia Z, Li
Q, Le X, Wang H, Yao J and Xie K: Therapeutic inhibition of Sp1
expression in growing tumors by mithramycin a correlates directly
with potent antiangiogenic effects on human pancreatic cancer.
Cancer. 110:2682–2690. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang L, Wei D, Huang S, Peng Z, Le X, Wu
TT, Yao J, Ajani J and Xie K: Transcription factor Sp1 expression
is a significant predictor of survival in human gastric cancer.
Clin Cancer Res. 9:6371–6380. 2003.PubMed/NCBI
|
|
39
|
Chintharlapalli S, Papineni S, Ramaiah SK
and Safe S: Betulinic acid inhibits prostate cancer growth through
inhibition of specificity protein transcription factors. Cancer
Res. 67:2816–2823. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mao Y, Chen H, Lin Y, Xu X, Hu Z, Zhu Y,
Wu J, Xu X, Zheng X and Xie L: microRNA-330 inhibits cell motility
by downregulating Sp1 in prostate cancer cells. Oncol Rep.
30:327–333. 2013.PubMed/NCBI
|
|
41
|
Hsu TI, Wang MC, Chen SY, Yeh YM, Su WC,
Chang WC and Hung JJ: Sp1 expression regulates lung tumor
progression. Oncogene. 31:3973–3988. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yao JC, Wang L, Wei D, Gong W, Hassan M,
Wu TT, Mansfield P, Ajani J and Xie K: Association between
expression of transcription factor Sp1 and increased vascular
endothelial growth factor expression, advanced stage, and poor
survival in patients with resected gastric cancer. Clin Cancer Res.
10:4109–4117. 2004. View Article : Google Scholar : PubMed/NCBI
|
